Cargando…
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensit...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749542/ https://www.ncbi.nlm.nih.gov/pubmed/26859456 http://dx.doi.org/10.1016/j.ccell.2016.01.002 |
_version_ | 1782415283574538240 |
---|---|
author | Ham, Jungoh Costa, Carlotta Sano, Renata Lochmann, Timothy L. Sennott, Erin M. Patel, Neha U. Dastur, Anahita Gomez-Caraballo, Maria Krytska, Kateryna Hata, Aaron N. Floros, Konstantinos V. Hughes, Mark T. Jakubik, Charles T. Heisey, Daniel A.R. Ferrell, Justin T. Bristol, Molly L. March, Ryan J. Yates, Craig Hicks, Mark A. Nakajima, Wataru Gowda, Madhu Windle, Brad E. Dozmorov, Mikhail G. Garnett, Mathew J. McDermott, Ultan Harada, Hisashi Taylor, Shirley M. Morgan, Iain M. Benes, Cyril H. Engelman, Jeffrey A. Mossé, Yael P. Faber, Anthony C. |
author_facet | Ham, Jungoh Costa, Carlotta Sano, Renata Lochmann, Timothy L. Sennott, Erin M. Patel, Neha U. Dastur, Anahita Gomez-Caraballo, Maria Krytska, Kateryna Hata, Aaron N. Floros, Konstantinos V. Hughes, Mark T. Jakubik, Charles T. Heisey, Daniel A.R. Ferrell, Justin T. Bristol, Molly L. March, Ryan J. Yates, Craig Hicks, Mark A. Nakajima, Wataru Gowda, Madhu Windle, Brad E. Dozmorov, Mikhail G. Garnett, Mathew J. McDermott, Ultan Harada, Hisashi Taylor, Shirley M. Morgan, Iain M. Benes, Cyril H. Engelman, Jeffrey A. Mossé, Yael P. Faber, Anthony C. |
author_sort | Ham, Jungoh |
collection | PubMed |
description | Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to the BCL-2 inhibitor ABT-199. This sensitivity occurs in part through low anti-apoptotic BCL-xL expression, high pro-apoptotic NOXA expression, and paradoxical, MYCN-driven upregulation of NOXA. Screening for enhancers of ABT-199 sensitivity in MYCN-amplified neuroblastomas, we demonstrate that the Aurora Kinase A inhibitor MLN8237 combines with ABT-199 to induce widespread apoptosis. In diverse models of MYCN-amplified neuroblastoma, including a patient-derived xenograft model, this combination uniformly induced tumor shrinkage, and in multiple instances led to complete tumor regression. |
format | Online Article Text |
id | pubmed-4749542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Cell Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47495422016-02-29 Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination Ham, Jungoh Costa, Carlotta Sano, Renata Lochmann, Timothy L. Sennott, Erin M. Patel, Neha U. Dastur, Anahita Gomez-Caraballo, Maria Krytska, Kateryna Hata, Aaron N. Floros, Konstantinos V. Hughes, Mark T. Jakubik, Charles T. Heisey, Daniel A.R. Ferrell, Justin T. Bristol, Molly L. March, Ryan J. Yates, Craig Hicks, Mark A. Nakajima, Wataru Gowda, Madhu Windle, Brad E. Dozmorov, Mikhail G. Garnett, Mathew J. McDermott, Ultan Harada, Hisashi Taylor, Shirley M. Morgan, Iain M. Benes, Cyril H. Engelman, Jeffrey A. Mossé, Yael P. Faber, Anthony C. Cancer Cell Article Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to the BCL-2 inhibitor ABT-199. This sensitivity occurs in part through low anti-apoptotic BCL-xL expression, high pro-apoptotic NOXA expression, and paradoxical, MYCN-driven upregulation of NOXA. Screening for enhancers of ABT-199 sensitivity in MYCN-amplified neuroblastomas, we demonstrate that the Aurora Kinase A inhibitor MLN8237 combines with ABT-199 to induce widespread apoptosis. In diverse models of MYCN-amplified neuroblastoma, including a patient-derived xenograft model, this combination uniformly induced tumor shrinkage, and in multiple instances led to complete tumor regression. Cell Press 2016-02-08 /pmc/articles/PMC4749542/ /pubmed/26859456 http://dx.doi.org/10.1016/j.ccell.2016.01.002 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ham, Jungoh Costa, Carlotta Sano, Renata Lochmann, Timothy L. Sennott, Erin M. Patel, Neha U. Dastur, Anahita Gomez-Caraballo, Maria Krytska, Kateryna Hata, Aaron N. Floros, Konstantinos V. Hughes, Mark T. Jakubik, Charles T. Heisey, Daniel A.R. Ferrell, Justin T. Bristol, Molly L. March, Ryan J. Yates, Craig Hicks, Mark A. Nakajima, Wataru Gowda, Madhu Windle, Brad E. Dozmorov, Mikhail G. Garnett, Mathew J. McDermott, Ultan Harada, Hisashi Taylor, Shirley M. Morgan, Iain M. Benes, Cyril H. Engelman, Jeffrey A. Mossé, Yael P. Faber, Anthony C. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination |
title | Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination |
title_full | Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination |
title_fullStr | Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination |
title_full_unstemmed | Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination |
title_short | Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination |
title_sort | exploitation of the apoptosis-primed state of mycn-amplified neuroblastoma to develop a potent and specific targeted therapy combination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749542/ https://www.ncbi.nlm.nih.gov/pubmed/26859456 http://dx.doi.org/10.1016/j.ccell.2016.01.002 |
work_keys_str_mv | AT hamjungoh exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT costacarlotta exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT sanorenata exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT lochmanntimothyl exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT sennotterinm exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT patelnehau exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT dasturanahita exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT gomezcaraballomaria exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT krytskakateryna exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT hataaaronn exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT floroskonstantinosv exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT hughesmarkt exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT jakubikcharlest exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT heiseydanielar exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT ferrelljustint exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT bristolmollyl exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT marchryanj exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT yatescraig exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT hicksmarka exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT nakajimawataru exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT gowdamadhu exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT windlebrade exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT dozmorovmikhailg exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT garnettmathewj exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT mcdermottultan exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT haradahisashi exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT taylorshirleym exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT morganiainm exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT benescyrilh exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT engelmanjeffreya exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT mosseyaelp exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination AT faberanthonyc exploitationoftheapoptosisprimedstateofmycnamplifiedneuroblastomatodevelopapotentandspecifictargetedtherapycombination |